Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE AND STAVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE AND STAVUDINE.
EMTRICITABINE vs LAMIVUDINE AND STAVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Stavudine is also an NRTI that inhibits HIV-1 reverse transcriptase after phosphorylation to stavudine triphosphate.
200 mg orally once daily, typically in combination with other antiretroviral agents.
Lamivudine 150 mg and stavudine 30-40 mg (depending on body weight: <60 kg: stavudine 30 mg; ≥60 kg: stavudine 40 mg) orally twice daily.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: Terminal half-life 5-7 hours (adults) to 10-12 hours (neonates); intracellular triphosphate half-life 10.5-15.5 hours, allowing once-daily dosing. Stavudine: Terminal half-life 1.0-1.6 hours but intracellular triphosphate half-life 3.5-4 hours, supporting twice-daily dosing.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: Approximately 70% of dose excreted unchanged in urine via glomerular filtration and active tubular secretion; 5-10% as trans-sulfoxide metabolite; fecal excretion <10%. Stavudine: Approximately 40% of dose excreted unchanged in urine via glomerular filtration and active tubular secretion; remainder metabolized to thymine and other metabolites; renal excretion accounts for ~60% of elimination.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."